This article is more than 5 years old. Information may no longer be current.

Quidel acquires InflammaDry, AdenoPlus

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Quidel Corp. announced the completed acquisition of the InflammaDry and AdenoPlus diagnostic businesses from RPS Diagnostics, a developer and manufacturer of rapid, point-of-care diagnostic tests for the eye health and primary care markets, for approximately $14 million in cash.

The InflammaDry and AdenoPlus are rapid, lateral flow-based, point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye, according to a press release from the company.

InflammaDry detects elevated levels of MMP-9, a key inflammatory marker for dry eye.

AdenoPlus differentiates between a viral and bacterial infection of acute conjunctivitis.

Both products are CE-marked, FDA-cleared, CLIA-waived and complement Quidel’s existing rapid diagnostic testing solutions, according to the company.

Manufacturing for both products will take place at Quidel’s San Diego facility.

Source: www.cga.ct.gov